- The World Health Organization (WHO) has published its first guideline for Ebola virus disease therapeutics, with new recommendations for using two monoclonal antibodies.
- Following a systematic review and meta-analysis, WHO recommended two monoclonal antibody treatments, Ebanga (Ansuvimab, mAb114) and Inmazeb (REGN-EB3).
- Regeneron Pharmaceuticals Inc's REGN Inmazeb became the first treatment for the ebola virus when it received FDA approval in October 2020.
- Merck & Co Inc's MRK COVID-19 partner treatment Ridgeback Biotherapeutics scored FDA approval for Ebanga in December 2020.
- Ridgeback in-licensed Ebanga from the National Institute of Allergy and Infectious Diseases in 2018.
- The two recommended therapeutics have demonstrated clear benefits and, therefore, can be used for all patients confirmed positive for Ebola virus disease, including older people, pregnant and breastfeeding women, children, and newborns born to mothers with confirmed Ebola within the first seven days after birth.
- The agency has also recommended not using ZMapp from privately held Mapp Biopharmaceutical and Gilead Sciences Inc's GILD remdesivir.
- All these recommendations only apply to Ebola virus disease caused by Ebola virus (EBOV; Zaire ebolavirus).
- Price Action: REGN shares are down 0.78% at $619.16 on the last check Thursday.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.